How to keep your pets calm during Fourth of July fireworks
While we celebrate our Independence Day, here's how to keep your four-legged friends safe and happy:
Petting your dog
If possible, your dog should stay home with at least one human so it can be reassured if it gets anxious. Stay with your pet in a room that has minimal windows and play soft music or a movie to distract from fireworks and other noises. A little affection goes a long way – one of the best ways to calm your dog down is to give it strong, firm pats to let it know you're there, says veterinarian Diana Watkins, who owns 143 Veterinary Services in Massachusetts.
Thundershirt
You can try anxiety-reducing devices like a Thundershirt, which acts like a weighted blanket to soothe your dog.
Medication
For extra-nervous dogs, there are situational anxiety medications your vet can prescribe. They can be helpful during loud sensory events like thunderstorms and fireworks or when you're leaving your dog alone for longer than normal.
Watkins advises giving your dog only veterinary-grade products because over-the-counter anti-anxiety and CBD supplements are often not FDA-regulated and can be harmful to your pup.
Collar with ID
Make sure your pet has an ID tag on at all times, or invest in a GPS locator for its collar if your pet isn't microchipped.
Take a walk before nighttime
It's a good idea to time walks earlier in the day before the fireworks start. Keep your dog on lead if you think fireworks will be set off.
Consider Hiring a Trainer
If fireworks and fear is impacting your animal, you can consider hiring a trainer. Working with a trainer of behavior consultant to desensitize your dog to fireworks gradually. It's never to late to plan for the next fireworks event.
Sources: USA TODAY Network reporting and research; American Kennel Club
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Ways to create a dementia-friendly environment during the Fourth of July
LANSING, Mich. (WLNS) — With the Fourth of July approaching quickly, it's important to remember that fireworks celebrations are not for everyone. This includes pets, veterans and those living with dementia. The Alzheimer's Foundation of America (AFA) created the 'F.O.U.R.' steps to creating a dementia-friendly Fourth of July. 'Fireworks and loud noises can create challenges for individuals living with dementia, which is why families need to make thoughtful, proactive adjustments to help their loved ones with dementia celebrate and enjoy Independence Day,' said Jennifer Reeder, LCSW, SIFI, senior director of educational and social services at AFA. 'Being prepared and adaptable are the best ways caregivers can create a dementia-friendly 4th of July for their loved ones.' If someone is a war veteran, AFA says the noises that come from fireworks can be triggering and mistaken for gunshots or bombs. Being inside at times when they are likely to hear fireworks is a good precaution. 'Even if that person is inside, they still may be in an area where fireworks are going off,' Chris Schneider, director of media relations at AFA said. 'That can be leaving the air conditioning on, getting a white noise machine or playing soothing, familiar music. All of that can help muffle some of those sounds.' It can also be helpful to check in on your loved one throughout the night if they live with you. Large crowds can be overwhelming for someone living with dementia. If you are hosting a gathering, limit guests to a few family members and close friends. AFA says name tags could be beneficial. 'Structure the celebration around the person's routine,' Schneider said. 'Routine disruptions can be troubling for someone living with dementia. If they normally eat at a certain time, build that into the day. If they usually take a nap at a certain time, build that into the day.' The AFA says to revise how you celebrate. The organization mentions that living with dementia shouldn't limit how someone celebrates Independence Day. Caregivers could make patriotic decorations and crafts, or look through a family album with pictures of previous Fourth of July celebrations. Both are dementia-friendly activities. Schneider says anyone looking for additional guidance can do so on their website. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Los Angeles Times
33 minutes ago
- Los Angeles Times
Here's how to get GLP-1 drugs covered by employer health insurance
While the new anti-obesity medications known as GLP-1s are only one tool to combat obesity and cardiometabolic disease, they have changed the medical landscape and are clinically important in treating these diseases. Yet most Americans who have health insurance cannot get coverage for them. For some, the only option has been to resort to compounded drugs for which the Food and Drug Administration has not assured the safety, and for which the main pharmaceutical ingredient is made in Chinese chemical factories without the quality standards of FDA-approved branded drugs. Even that inferior option is going away, as the FDA has declared that the name-brand drugs are no longer in short supply and so the off-brand drugs are no longer allowed. President Trump recently called out 'the fat shot' when he told pharmaceutical companies to offer the United States the same pricing they offer other peer nations. He related a story of a friend in London who told him the price of GLP-1s there is about one-tenth of what it would cost in the U.S. The average listed price in the U.S. is more than $1,000 a month. In England, it is about $150. There is not yet legislative authority to require pharmaceutical companies to sell prescription drugs in the United States at lower prices, but there is a straightforward way that these medications can become affordable to many in the United States. Most employee health insurance coverage is through employer-sponsored plans, in which the budget is based on premiums contributed by both the employer and employee. Few plans provide coverage for any weight loss treatment, but if they did, it would have to fit in that budget — which would probably necessitate raising premiums. Toxic fat is the cause of many cardiometabolic conditions, and GLP-1 drugs can help people reclaim their health. Improving access and affordability could be transformative for public health, given that about 88% of Americans are metabolically unhealthy. Increasingly, employees are telling their employers that they want access to these medications, and many employers would like to offer plans that cover them. The brand-name manufacturers themselves provide a clue to how this could be possible. They offer their drugs directly to patients for around $500 a month. The sticking points? People whose employee-sponsored health insurance would cover even part of the cost of weight loss drugs are not eligible for that reduced price. Also, at $500 a month, even the discounted direct-to-consumer price still makes the drugs unaffordable to many. Drug pricing in the United States is not transparent, and many entities get a share of the dollars that the health plans have budgeted. Simplifying the system with the GLP-1 drugs could make these drugs more accessible. Today, a drug bought from the drug company at $1,000 can include around a $300 rebate negotiated by a pharmacy benefit manager (working on behalf of the employer-sponsored health plan) and is often accompanied by a $150 manufacturer's discount coupon. The resulting price is similar to the around $500 price that drug companies offer directly to patients who don't have coverage for these drugs. If we eliminate the rebates and coupons, so that manufacturers only charge employer-sponsored health plans the same $500 price they charge consumers directly, and then allow employers to contribute part of the cost (say $300 a month), we can get the out-of-pocket costs for employees close to the price at which these drugs are sold in other countries. It would be a rebate-free, coupon-free system with reasonable cost sharing by the employer. The only reason that system of rebates even came to exist was to create enticements so certain manufacturers could persuade pharmacy benefit managers and employee-sponsored health plans to favor their drug over others'. But in this case, where only two main drugs exist and both have publicly available clinical trial data that physicians can use to make informed prescribing decisions, rebates aren't needed. In reality, recent agreements between pharmacy benefit managers and drug manufacturers have prioritized financial interests over clinical appropriateness, determining drug preference based on what benefits the companies, not what's best for the patient. Getting the price of the drugs to an affordable level would significantly remove one of the most despised aspects of the healthcare system — prior approval authorization. Doctors' offices are expending resources to get around barriers erected to limit the use of healthcare plan dollars on expensive medications for those the insurance plan and its managers determine do not need the drug, even when the doctors believe they do. GLP-1s are highly effective for most people, but they also have some serious risks. We should leave it to doctors to make shared decisions with their patients about whether the risks outweigh the benefits. To further create incentives for the pharmaceutical companies to reduce their prices and for employers to share in the cost of these drugs, the Trump administration should agree, as the Biden administration did, to cover them under Medicare. (Trump reversed that effort this year, barring Medicare and Medicaid from using them to treat the disease of obesity.) This plan to simplify payments and expand access would not make all drugs affordable in the United States, but increasing accessibility to GLP-1s can get us on the road to eliminating the significant problem of cardiometabolic disease and improving our health. David A. Kessler, a former commissioner of the Food and Drug Administration, is the author of 'Diet, Drugs, and Dopamine: The New Science of Achieving a Healthy Weight.'
Yahoo
36 minutes ago
- Yahoo
Enrolment concludes in Belite Bio's trial of Tinlarebant for geographic atrophy
Belite Bio has completed enrolment in the 24-month PHOENIX Phase III trial assessing the tolerability and safety of oral Tinlarebant in individuals with geographic atrophy (GA) in dry age-related macular degeneration (AMD). This multicentre, randomised, placebo-controlled, double-masked, global trial is crucial in evaluating the therapy's potential to minimise the atrophic lesion growth rate in these patients. It has enrolled 500 participants across various sites in the US, the UK, the Czech Republic, France, Switzerland, Taiwan, Australia, and China. Tinlarebant, a one-daily tablet, is being developed as an early intervention to preserve retinal tissue health and integrity in those with Stargardt disease type 1 (STGD1) and GA. At present, there are no treatments approved by the Food and Drug Administration (FDA) for STGD1 and no approved oral treatments for GA. The tablet has received fast track, rare paediatric disease, and breakthrough therapy designations in the US, orphan drug status in the US, Japan, and Europe, and Sakigake designation in Japan for STGD1. Tinlarebant is also being evaluated in a Phase III trial (DRAGON) and a Phase II/III trial (DRAGON II) for adolescent STGD1 individuals, in addition to the PHOENIX trial for GA subjects. Belite Bio CEO and chairman Dr Tom Lin said: 'Completing enrolment in the PHOENIX trial marks an important milestone for Belite Bio as we advance our lead candidate, Tinlarebant, for the treatment of geographic atrophy. 'This achievement brings us one step closer to evaluating the potential of Tinlarebant to slow atrophic lesion growth in this serious and progressive disease for which there are no approved oral treatments. There remains a significant unmet need for this patient population.' The company develops new treatments for degenerative retinal diseases like STGD1 and GA. Last year, the company submitted an application to the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) to initiate a trial of Tinlarebant for adolescent STGD1 treatment. "Enrolment concludes in Belite Bio's trial of Tinlarebant for geographic atrophy" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
